Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $23.00 Average Price Target from Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been given a consensus rating of “Buy” by the six ratings firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $23.00.

A number of research analysts recently commented on the stock. B. Riley initiated coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They issued a “buy” rating and a $28.00 target price on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 16th. Finally, Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th.

Theravance Biopharma Trading Up 3.8%

Shares of NASDAQ:TBPH opened at $15.22 on Friday. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $15.34. The company’s 50 day moving average is $14.12 and its two-hundred day moving average is $11.94. The company has a market cap of $766.48 million, a PE ratio of 63.42 and a beta of 0.07.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TBPH. Bank of New York Mellon Corp lifted its position in shares of Theravance Biopharma by 1.5% during the first quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company’s stock worth $1,049,000 after purchasing an additional 1,720 shares in the last quarter. Tabor Asset Management LP acquired a new stake in Theravance Biopharma in the first quarter valued at $135,000. Brookwood Investment Group LLC acquired a new stake in Theravance Biopharma in the first quarter valued at $188,000. GSA Capital Partners LLP raised its holdings in Theravance Biopharma by 11.9% in the first quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company’s stock valued at $1,628,000 after acquiring an additional 19,363 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in Theravance Biopharma by 20.8% in the first quarter. XTX Topco Ltd now owns 19,759 shares of the biopharmaceutical company’s stock valued at $176,000 after acquiring an additional 3,403 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.